Rob Dillard

DocwireNews

The safety and efficacy of luspatercept is favorable for treating anemia in patients with myelofibrosis, according to a study by lead author Aaron Thomas Gerds and colleagues that will be presented at the 2023 American Society of Clinical Oncology Annual Meeting.Patients were stratified into 4 cohorts based on transfusion dependence (TD) and stable ruxolitinib treatment. Cohort 1 patients had no TD and did not receive ruxolitinib, cohort 2 patients had TD and did not receive ruxolitinib, cohort 3A patients had no TD and received ruxolitinib, and cohort 3B patients had TD and received ruxolitinib. All patients received subcutaneous luspatercept 1.0 mg/kg (1.33 mg/kg for patients in the cohort 3B expansion) with titration up to 1.75 mg/kg in 21-day cycles.The study&rsquo;s key end point was anemia response from baseline without transfusion or free of red blood cell transfusion. The secondary outcomes were duration of response, transfusion frequency, change in Hgb level, and symptom response.Over an average treatment duration of 42.8 weeks, the results showed that cohort 3B had the highest anemia response rate at 26.3% (95% CI, 13.4-43.1), with patients transfusion-independent during the primary treatment period and 31.6% (95% CI, 17.5-48.7) of patients transfusion-independent during the entire treatment period. Half of the patients in cohort 3B saw a reduced transfusion burden during the primary treatment period; more than 21% achieved mean Hgb increase &ge;1.5 g/dL from baseline throughout the entire treatment period, and nearly 16% achieved a 50% or more reduction in symptom score from baseline. However, researchers also noted that 47.4% of patients had at least 1 treatment-related adverse event, most frequently hypertension. A total of 9 patients died during treatment from postprocedural hemorrhage, pneumonia, intracranial hemorrhage, septic shock, ischemic stroke, multiple organ dysfunction syndrome, renal failure, pneumonitis, and myelofibrosis, but no deaths were linked to the study drug.&ldquo;In [patients] with MF, the safety profile of luspatercept was consistent with previous studies, and efficacy results showed promising improvements in anemia and transfusion burden in all cohorts.&rdquo;Source: Gerds AT, Harrison C, Kiladjian JJ, et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: results from the ACE-536-MF-001 study. Abstract #7016. Published for the 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, Illinois.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Luspatercept Appears Safe and Effective for Treating Anemia in Patients With Myelofibrosis

ASCO 2023

Luspatercept Appears Safe and Effective for Treating Anemia in Patients With Myelofibrosis.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe